Novo Nordisk’s Wegovy weight loss drug approved in China

[Pelican Press 0]

Novo Nordisk’s Wegovy weight loss ***** approved in China

Novo Nordisk’s Wegovy weight loss ***** has seen a meteoric rise in popularity. 

Nurphoto | Getty Images

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster ***** for ***** in the world’s second largest economy.

China’s National Medical Products Administration “recently” approved the weekly injectable *****, Novo Nordisk said in

This is the hidden content, please

• Sign In
• or
• Sign Up

on the ******** version of its website, according to

This is the hidden content, please

• Sign In
• or
• Sign Up

translate.

The ***** will initially be available to patients with a body mass index (BMI) of 30kg/m² — the threshold for obesity — and at least one weight-related comorbidity, it added. Weight-related comorbidities refer to additional medical conditions that someone with obesity can develop due to their weight.

Novo Nordisk did not immediately respond to CNBC’s request for further information on the proposed pricing and rollout timeline of the drugs. The Danish pharmaceutical giant

This is the hidden content, please

• Sign In
• or
• Sign Up

it would initially focus on patients paying out-of-pocket, Reuters reported.

Novo Nordisk shares were up 1.8% as of 9:18 a.m. London time.

The approval comes as the patent on the *****’s active ingredient, Semaglutide, is set to expire in China in 2026 and as competition heats up from domestic ***** makers in the market.

More than half of China’s 1.4 billion population are overweight or obese, according to

This is the hidden content, please

• Sign In
• or
• Sign Up

from the country’s National Health Commission.

Meanwhile, clinical trial records show around 15 generic versions of Ozempic and Wegovy are currently being developed in China,

This is the hidden content, please

• Sign In
• or
• Sign Up

last month.

The company’s Ozempic diabetes ***** was approved in 2021 and saw sales in the greater China region double last year.

Novo Nordisk and competitor Eli Lilly have been struggling to keep up with surging demand for their obesity treatments.

On Monday, Novo Nordisk announced it is investing $4.1 billion to expand its manufacturing in the U.S. Extra capacity from a new manufacturing plant in Clayton, North Carolina is expected to be completed between 2027 and 2029.

This is the hidden content, please

• Sign In
• or
• Sign Up

Business,Biotech and Pharmaceuticals,Biotechnology,Pharmaceuticals,Novo Nordisk A/S,Eli Lilly and Co,business news
#Novo #Nordisks #Wegovy #weight #loss #***** #approved #China

This is the hidden content, please

• Sign In
• or
• Sign Up